Table 4.
Summary of vitamin D study characteristics and VC outcome
| Author and Year | Type of Study | Study Duration (months) | Participant | Intervention (Participants at Baseline) | Comparator (Participants at Baseline) | VC as Primary or Secondary End Point | VC Imaging | VC Site | VC Outcome |
|---|---|---|---|---|---|---|---|---|---|
| Baker 198657 | RCT | 60 | HD | Calcitriol, n=38 | Placebo, n=38 | Secondary | X-ray | Hands, feet, pelvis, coronary artery | No significant VC attenuation at all sites |
| Morosetti 200858 | Non-RCT | 24 | HD | High-dose calcitriol, n=18 | Low-dose calcitriol + sevelamer, n=18 | Primary | CT | Coronary artery | No significant VC attenuation |
| Delanaye 201359 | RCT | 12 | HD, serum 25(OH)D <30 ng/ml | Cholecalciferol, n=22 | Placebo, n=21 | Secondary | X-ray lateral | Abdominal aorta | No significant VC attenuation |
| Kidir 201560 | Non-RCT | 6 | HD or PD | Cholecalciferol, n=26 | Standard treatment, n=17 | Primary | X-ray hand & pelvis | Radial arteries, digital arteries, iliac arteries, femoral arteries | No significant VC attenuation at all sites |
| Samaan 201961 | RCT | 18 | CKD stage 3–4, serum 25(OH)D <30 ng/ml | Cholecalciferol, n=23 | Placebo, n=24 | Primary | CT | Coronary artery | No significant VC attenuation |
| Anis 202062 | RCT | 11 (48 weeks) | CKD stage 3–4 with SHPT | Calcitriol, n=22 | Paricalcitol, n=22 | Primary | CT | Coronary artery, aortic valve, mitral valve | No significant VC attenuation at all sites |
HD, hemodialysis; PD, peritoneal dialysis.